Ionis Pharmaceuticals IONS License — Revenue
Discontinued — last reported Q3 '19
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed November 6, 2019, on SEC EDGAR. View the filing →
Questions, answered.
- What does license — revenue mean?
- Revenue earned by granting other companies the rights to use proprietary technology or drug candidates through licensing agreements.
- How do you interpret license — revenue?
- An increase suggests successful execution of R&D partnerships, achievement of clinical or regulatory milestones, or strong demand for the company's proprietary technology platform. A decrease may indicate a lull in partnership activity, the completion of milestone payments, or challenges in advancing the pipeline to stages that trigger contractual payments.
- How does license — revenue compare across companies?
- Commonly reported by biotechnology and pharmaceutical companies as 'collaboration revenue' or 'license and milestone revenue,' often fluctuating significantly based on the timing of clinical trial results and regulatory filings.